HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterated a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $50 price target.
May 23, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterated a Neutral rating on Sage Therapeutics and maintained a $50 price target.
The news of HC Wainwright & Co. analyst reiterating a Neutral rating on Sage Therapeutics and maintaining a $50 price target is directly related to the company. However, since the rating is neutral, it is not expected to have a significant short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100